Islet Function In Gestational Diabetes

Overview

About this study

The purpose of this study is to define the contribution of α-cell function to glucose tolerance in pregnancy and postpartum in women with and without GDM.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Women between 20 and 40, years of age

  • Women with and without GDM (Carpenter and Coustan Criteria)

  • Women will be pregnant with a viable, singleton pregnancy

  • Women will have completed their 2nd trimester glucose testing with a 50g glucose 1 hour challenge test +/- a 100 g oral glucose tolerance test (OGTT)

Exclusion Crriteria:

  • Women <20 or >40 years

  • Active systemic illness (such as chronic kidney disease, hypertension etc.) including a prepregnancy diagnosis of diabetes mellitus

  • Multiple gestation, major anomaly or non-viable pregnancy on ultrasound

  • Fasting glucose ≥ 100mg/dL or HbA1c ≥5.7% in early pregnancy, one abnormal value on 3-hour 100g OGTT or glucose ≥190 mg/dL on a glucose challenge test (GCT) with no subsequent 3-hour OGTT completed

  • Taking medication that affects glucose metabolism before pregnancy or in early pregnancy (prior to GDM screening)

  • Taking any glucose lowering medication (e.g. metformin, glyburide) other than insulin to treat GDM in the current pregnancy

  • History of upper GI surgery that alters gastric emptying e.g., bariatric surgery

  • Hemoglobin < 11g/dL

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 06/28/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Aoife Egan, M.B., B.Ch., Ph.D.

Contact us for the latest status

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions